SUVENSuven Life Sciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUVEN — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.03
- • Promoter holding: 66.6%
- • RSI: 61
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month return: +26.2%
Bull case
- • Debt/Equity: 0.03
- • Promoter holding: 66.6%
- • RSI: 61
- • MACD: bullish
Bear case
- • Revenue growth: 3.6% YoY
- • Profit growth: -71.9% YoY
- • Volume: 0.6x 20-day average
- • Volume trend: 0.8x baseline
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 3.6% YoY
- • Profit growth: -71.9% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹20.48). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.